Extension of in vivo half-life of biologically active molecules by XTEN protein polymers.
暂无分享,去创建一个
V. Schellenberger | Vladimir N Podust | V. Podust | Volker Schellenberger | Bee-Cheng Sim | R. Peters | Sibu Balan | Michael P Coyle | Ulrich Ernst | Robert T Peters | B. Sim | S. Balan | Michael P. Coyle | Ulrich P. Ernst
[1] F. Perez-Ruiz,et al. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. , 2008, Advanced drug delivery reviews.
[2] A. Tsourkas,et al. Quantitative Comparison of Tumor Delivery for Multiple Targeted Nanoparticles Simultaneously by Multiplex ICP-MS , 2014, Scientific Reports.
[3] Ian Kimber,et al. Immunogenicity of therapeutic proteins: Influence of aggregation , 2013, Journal of immunotoxicology.
[4] T. Bailey,et al. A Long-Acting Human Growth Hormone With Delayed Clearance (VRS-317): Results of a Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Growth Hormone–Deficient Adults , 2013, The Journal of clinical endocrinology and metabolism.
[5] Inger Sandlie,et al. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics , 2015, Front. Immunol..
[6] R. Offord,et al. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. , 1996, Bioconjugate chemistry.
[7] W. Stemmer,et al. GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model , 2012, PloS one.
[8] M. Scholle,et al. Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose , 2010, PloS one.
[9] B. Larijani,et al. The importance of hypoglycemia in diabetic patients , 2012, Journal of Diabetes & Metabolic Disorders.
[10] D. DiMichele. Inhibitors in Hemophilia: A Primer , 2008 .
[11] T. Parry,et al. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. , 2002, European journal of pharmacology.
[12] Andrew Tsourkas,et al. ICP-MS analysis of lanthanide-doped nanoparticles as a non-radiative, multiplex approach to quantify biodistribution and blood clearance. , 2012, Biomaterials.
[13] K. Geoghegan,et al. Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. , 1992, Bioconjugate chemistry.
[14] D. Dunger,et al. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. , 2003, Diabetes care.
[15] S. Harding,et al. Hydrodynamic characterisation of chemically degraded hyaluronic acid , 2003 .
[16] F. Szoka,et al. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. , 2015, Advanced drug delivery reviews.
[17] Stephan M. Koza,et al. Size-Exclusion Chromatography for the Analysis of Protein Biotherapeutics and their Aggregates , 2012, Journal of liquid chromatography & related technologies.
[18] R. Kontermann,et al. Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives , 2012 .
[19] I. Kaltashov,et al. Structural characterization of protein–polymer conjugates. I. Assessing heterogeneity of a small PEGylated protein and mapping conjugation sites using ion exchange chromatography and top-down tandem mass spectrometry , 2012 .
[20] V. Lubchenko,et al. The use of dynamic light scattering and brownian microscopy to characterize protein aggregation. , 2011, The Review of scientific instruments.
[21] J. Holst,et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. , 2000, The Journal of clinical endocrinology and metabolism.
[22] Lihua Huang,et al. Elucidation of PEGylation site with a combined approach of in-source fragmentation and CID MS/MS , 2010, Journal of the American Society for Mass Spectrometry.
[23] K. Campbell,et al. Staining of the Ca2+-binding proteins, calsequestrin, calmodulin, troponin C, and S-100, with the cationic carbocyanine dye "Stains-all". , 1983, The Journal of biological chemistry.
[24] A. Klibanov,et al. Hydrophobic salts markedly diminish viscosity of concentrated protein solutions , 2011, Biotechnology and bioengineering.
[25] J. Aronson. Safety , 2009, BMJ : British Medical Journal.
[26] J. Mahlangu,et al. Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[27] Jan Jezek,et al. Viscosity of concentrated therapeutic protein compositions. , 2011, Advanced drug delivery reviews.
[28] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[29] R. Rosenfeld,et al. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[30] B. E. Kimmel,et al. Optimized clinical performance of growth hormone with an expanded genetic code , 2011, Proceedings of the National Academy of Sciences.
[31] C. Gu,et al. Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. , 2013, Protein engineering, design & selection : PEDS.
[32] M. Mouksassi,et al. Population Pharmacokinetics of Teduglutide Following Repeated Subcutanenous Administrations in Healthy Participants and in Patients With Short Bowel Syndrome and Crohn's Disease , 2010, Journal of clinical pharmacology.
[33] Yuanguo Cheng,et al. Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. , 2008, International journal of pharmaceutics.
[34] F. O'Brien,et al. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. , 2005, Pediatric endocrinology reviews : PER.
[35] E. Åkerblom,et al. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. , 1984, International archives of allergy and applied immunology.
[36] J. Stockman. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .
[37] G. Pasut. Polymers for Protein Conjugation , 2014 .
[38] Chee-Youb Won,et al. PEG-modified biopharmaceuticals. , 2009, Expert opinion on drug delivery.
[39] O. Tanner. Intensive versus Conventional Glucose Control in Critically Ill Patients , 2009 .
[40] D. Dunger,et al. Monitoring of concordance in growth hormone therapy , 2007, Archives of Disease in Childhood.
[41] R. Kaufman,et al. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[42] Costel C. Darie,et al. Trends in Characterization of PEGylated Proteins by Mass Spectrometry , 2014 .
[43] B. Hamm,et al. XTEN-Annexin A5: XTEN Allows Complete Expression of Long-Circulating Protein-Based Imaging Probes as Recombinant Alternative to PEGylation , 2014, The Journal of Nuclear Medicine.
[44] B. Trathnigg. Size Exclusion Chromatography of Polymers , 2003 .
[45] P. Donnan,et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin‐treated Type 2 diabetes: a population‐based study , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[46] M. A. Hartman,et al. Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility , 2014, Bioconjugate chemistry.
[47] B. Nielsen,et al. Recombinant Factor IX , 1997, Thrombosis and Haemostasis.
[48] Dimichele. Inhibitors in haemophilia: a primer , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[49] H. Heyneker,et al. High-level secretion of human growth hormone by Escherichia coli. , 1987, Gene.
[50] J. Gebler,et al. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. , 2009, Analytical chemistry.
[51] Francesco M Veronese,et al. State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[52] T. Nichols,et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. , 2011, Blood.
[53] J. Powell,et al. Longer‐acting clotting factor concentrates for hemophilia , 2015, Journal of thrombosis and haemostasis : JTH.
[54] W. Stemmer,et al. A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life , 2012, Journal of pharmaceutical sciences.
[55] M. Mouksassi,et al. Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon‐Like Peptide‐2 (GLP‐2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects , 2008, Journal of clinical pharmacology.
[56] Mohammed Shameem,et al. Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications , 2014, mAbs.
[57] Pascal Richette,et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents , 2012, Expert opinion on drug delivery.
[58] Ray Yin,et al. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers. , 2011, Journal of pharmacological and toxicological methods.
[59] A. Gunn,et al. Non-Compliance with Growth Hormone Treatment in Children Is Common and Impairs Linear Growth , 2011, PloS one.
[60] D. Rudmann,et al. High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins , 2013, Toxicologic pathology.
[61] N. Shah,et al. Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia , 2012, Diabetes Care.
[62] S. Schinner,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[63] P. Lenting,et al. The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.
[64] 荒井保明. Pharmacokinetics , 1993 .
[65] Lihua Huang,et al. Characterization of poly(ethylene glycol) and PEGylated products by LC/MS with postcolumn addition of amines. , 2009, Analytical chemistry.
[66] H. Goldberg,et al. The staining of acidic proteins on polyacrylamide gels: enhanced sensitivity and stability of "Stains-all" staining in combination with silver nitrate. , 1997, Analytical biochemistry.
[67] L. Vincent,et al. Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent Anti-Human Immunodeficiency Virus Type 1 Activity , 2009, Antimicrobial Agents and Chemotherapy.
[68] A. Dornhorst,et al. PREDICTIVE™– a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort , 2007, Diabetes, obesity & metabolism.
[69] P. Schnier,et al. Gas-phase proton-transfer chemistry coupled with TOF mass spectrometry and ion mobility-MS for the facile analysis of poly(ethylene glycols) and PEGylated polypeptide conjugates. , 2008, Analytical chemistry.
[70] Herbert J Meiselman,et al. Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.
[71] Willem P C Stemmer,et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner , 2009, Nature Biotechnology.
[72] Huub Schellekens,et al. The Immunogenicity of Polyethylene Glycol: Facts and Fiction , 2013, Pharmaceutical Research.
[73] S. Schmidt. Fusion Proteins for Half‐Life Extension , 2013 .
[74] Ambady Ramachandran,et al. Hypoglycemia: The neglected complication , 2013, Indian journal of endocrinology and metabolism.
[75] David J Brayden,et al. Advances in PEGylation of important biotech molecules: delivery aspects , 2008, Expert opinion on drug delivery.
[76] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[77] Kang-Choon Lee,et al. Emerging PEGylated drugs , 2009, Expert opinion on emerging drugs.
[78] G. Shopp,et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.
[79] K. Geoghegan,et al. Site‐Directed Conjugation of Nonpeptide Groups to Peptides and Proteins via Periodate Oxidation of a 2‐Amino Alcohol. Application to Modification at N‐Terminal Serine. , 1992 .